Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Alnylam Pharmaceuticals is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,665 staff and has a trailing 12-month revenue of around $960.9 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $224.91 |
|---|---|
| 52-week range | $117.58 - $242.97 |
| 50-day moving average | $227.22 |
| 200-day moving average | $187.48 |
| Wall St. target price | $246.39 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-7.49 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $224.91 from 2023-02-01
| 1 week (2023-01-27) | -2.79% |
|---|---|
| 1 month (2023-01-03) | -3.72% |
| 3 months (2022-11-03) | 4.26% |
| 6 months (2022-08-03) | 6.08% |
| 1 year (2022-01-30) | N/A |
|---|---|
| 2 years (2021-02-03) | 48.70% |
| 3 years (2020-02-03) | 96.15% |
| 5 years (2018-02-02) | 80.65% |
| Revenue TTM | $960.9 million |
|---|---|
| Gross profit TTM | $704.1 million |
| Return on assets TTM | -14.11% |
| Return on equity TTM | -343.51% |
| Profit margin | -123.02% |
| Book value | $-0.55 |
| Market capitalisation | $27.7 billion |
TTM: trailing 12 months
We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $117.58 up to $242.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 0.5033. This would suggest that Alnylam Pharmaceuticals's shares are less volatile than average (for this exchange).
Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.